NASDAQ:OBLN - Obalon Therapeutics Stock Price, Price Target & More

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics Inc (NASDAQ:OBLN) issued its quarterly earnings data on Monday, March, 5th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.12. The business earned $3.69 million during the quarter, compared to analyst estimates of $3.88 million. Obalon Therapeutics had a negative net margin of 399.94% and a negative return on equity of 102.17%. View Obalon Therapeutics' Earnings History.

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Obalon Therapeutics.

5 equities research analysts have issued 1-year price objectives for Obalon Therapeutics' stock. Their predictions range from $4.00 to $16.00. On average, they anticipate Obalon Therapeutics' stock price to reach $9.25 in the next year. View Analyst Ratings for Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include SeaSpine (SPNE), Apollo Endosurgery (APEN), Alphatec (ATEC), Restoration Robotics (HAIR), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Arch Therapeutics (ARTH), Motus GI (MOTS), Invuity (IVTY), Neovasc (NVCN), SANUWAVE (SNWV), Spectral Medical (EDTXF), iCAD (ICAD), Repro-Med Systems (REPR) and CAS Medical Systems (CASM).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

News coverage about OBLN stock has trended positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Obalon Therapeutics earned a media sentiment score of 0.42 on Accern's scale. They also assigned news articles about the company an impact score of 46.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Obalon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tamarack Advisers LP (2.42%), Massachusetts Financial Services Co. MA (1.78%), C WorldWide Group Holding A S (1.41%), Tiverton Asset Management LLC (0.43%) and Granite Investment Partners LLC (0.27%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Matthew Norwood, Neil Drake and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

OBLN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Granite Investment Partners LLC, C WorldWide Group Holding A S and Tiverton Asset Management LLC. View Insider Buying and Selling for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $2.54.

Obalon Therapeutics has a market capitalization of $44.64 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]